Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹8,698 cr of revenue in its latest quarter (Q2 FY27) and kept 10.6% of sales as profit. It is the 6th largest of 9 Pharmaceuticals companies we track, by market value.
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 61% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 16–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 75
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in DRREDDY?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 2%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹8,698 cr |
| Other Income | ₹156 cr |
| Total Income | ₹8,854 cr |
| Cost of Materials | ₹1,661 cr |
| Purchases of Stock-in-Trade | ₹1,538 cr |
| Inventory Change (±) | ₹-30 cr |
| Employee Benefit Expense | ₹1,612 cr |
| Finance Costs | ₹125 cr |
| Depreciation & Amortisation | ₹527 cr |
| Other Expenses | ₹2,187 cr |
| Total Expenses | ₹7,619 cr |
| Profit before Tax | ₹1,235 cr |
| Tax Expense | ₹314 cr |
| Share of JV / Associates | ₹-8 cr |
| Net Profit | ₹913 cr |
| Net margin on total income | 10.3% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 7,546 cr | 8,100 cr | 8,698 cr |
| Total income | 8,022 cr | 8,455 cr | 8,854 cr |
| Expenses | 7,827 cr | 7,902 cr | 7,619 cr |
| Profit before tax | 195 cr | 553 cr | 1,235 cr |
| Tax | -22 cr | 118 cr | 314 cr |
| Net profit (owners' share) | 221 cr | 444 cr | 925 cr |
| Net margin (owners' share, on revenue) | 2.9% | 5.5% | 10.6% |
| EPS (₹) | 2.65 | 5.33 | 11.10 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limitedthis company | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹8 / share | 10 Jul 2026 |
| Dividend | ₹8 / share | 10 Jul 2025 |
| Stock split | Stock Split From Rs.5/- to Rs.1/- | 28 Oct 2024 |
| Dividend | ₹40 / share | 16 Jul 2024 |
| Dividend | ₹40 / share | 11 Jul 2023 |
| Dividend | ₹30 / share | 11 Jul 2022 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.